# Nofima

peptide bioactivity research — pilot lines and clinical peptide trials for diabetes.

Source: https://en.bioecon.ru/companies/nofima/
Updated: 2026-06-28

- Country: Norway

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | The Research Council of Norway (projects included TailoTides, Pepfishing) | https://nofima.com/projects/pepfishing/, https://nofima.com/projects/sensor-guided-enzymatic-protein-hydrolysis-and-separation-technologies-for-tailored-biomanufacturing-of-bioactive-peptides/, https://nofima.com/results/tailored-peptides-a-key-to-better-health/ |
| Revenue | NOK 736 million (2024) | https://nofima.com/, https://nofima.com/about/ |
| Headcount | 371 employees | https://nofima.com/, https://nofima.com/about/ |
| Production site | Tromsø, Norway (Biotep facility at Nofima headquarters) | https://biotep.no/en/, https://biotep.no/om-biotep/, https://nofima.com/facility/biotep/ |
| Capacity | Can handle volumes from small batches up to 1,000 kg; flexible mini-factory scale | https://biotep.no/en/, https://biotep.no/ofte-stilte-sporsmal/ |
| Regulatory approval | Biotep is approved by the Norwegian Food Safety Authority (Mattilsynet) | https://biotep.no/en/, https://biotep.no/ofte-stilte-sporsmal/ |

Independent sources: biotep.no

## Technologies

- [Marine peptides & nutraceuticals](https://en.bioecon.ru/technology/marine-peptides-nutraceuticals/)